Innate Pharma (IPH) Q3 2024 earnings summary

Executive summary

• Jonathan Dickinson appointed CEO, bringing extensive oncology and pharma leadership experience and a focus on advancing the antibody-based and innate immunity pipeline.

• Strategic focus on proprietary R&D, advancing clinical assets, and leveraging partnerships for value creation in oncology.

• Pipeline includes seven clinical assets (three proprietary, four partnered), with an eighth entering phase I in early 2025, and multiple preclinical candidates.

• Achieved key regulatory milestones: FDA provided positive feedback on lacutamab's pathway and cleared IND for IPH4502.

• Multiple clinical and preclinical data presentations at major scientific meetings (ASH, ASCO, SITC) highlight pipeline progress.

Financial highlights

• Cash, cash equivalents, and financial assets totaled €96.4 million as of September 30, 2024, including €14.0 million in short-term investments and €10.3 million in non-current financial instruments.

• Financial liabilities stood at €33.2 million at quarter-end.

• Revenues for the first nine months of 2024 were €10.2 million, down from €36.5 million for the same period in 2023, mainly from collaboration and licensing agreements.

• Cash runway expected to fund operations through end of 2025.

Outlook and guidance

• Near-term catalysts include regulatory progress and potential partnership for lacutamab, phase I initiation for IPH4502, and continued advancement of ANKET programs.

• Initial safety, PK, and efficacy data for IPH6501 expected in 2025, with further clinical efficacy data in 2026.

• Monalizumab: Phase 3 PACIFIC-9 readout expected in 2025.